Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.
about
IL-17 and IL-22 in cerebrospinal fluid and plasma are elevated in Guillain-Barré syndromeModeling leukocyte trafficking at the human blood-nerve barrier in vitro and in vivo geared towards targeted molecular therapies for peripheral neuroinflammationInflammatory neuropathies: pathology, molecular markers and targets for specific therapeutic intervention.Dimethyl Fumarate Ameliorates Lewis Rat Experimental Autoimmune Neuritis and Mediates Axonal ProtectionRisk of Guillain-Barré syndrome following pandemic influenza A(H1N1) 2009 vaccination in Germany[Guillain-Barré syndrome after exposure to influenza].α(M)β(2)-integrin-intercellular adhesion molecule-1 interactions drive the flow-dependent trafficking of Guillain-Barré syndrome patient derived mononuclear leukocytes at the blood-nerve barrier in vitro.The role of chemokines in Guillain-Barré syndrome.Contrasting immune responses mediate Campylobacter jejuni-induced colitis and autoimmunityIdentification of gene networks and pathways associated with Guillain-Barré syndrome.Pathogenesis and treatment of immune-mediated neuropathies.Erythropoietin-derived nonerythropoietic peptide ameliorates experimental autoimmune neuritis by inflammation suppression and tissue protection.Chronic dysimmune neuropathies: Beyond chronic demyelinating polyradiculoneuropathy.Antiglycolipid antibodies in Guillain-Barré syndrome and related diseases: review of clinical features and antibody specificities.Treatment of Guillain-Barré syndrome and CIDP.Treatment of immune-mediated, dysimmune neuropathies.Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathiesCombined nerve and muscle biopsy in the diagnosis of vasculitic neuropathy. A 16-year retrospective study of 202 cases.A comparison between plasmapheresis and intravenous immunoglobulin in children with Guillain-Barré syndrome in Upper EgyptTranslational strategies in peripheral neuroinflammation and neurovascular repair.A novel myelin P0-specific T cell receptor transgenic mouse develops a fulminant autoimmune peripheral neuropathy.Accumulation of fascin+ cells during experimental autoimmune neuritis.Evidence-based treatment of chronic immune-mediated neuropathies.Guillain-barré syndrome: modern theories of etiology.Programmed Death Ligand 1 Plays a Neuroprotective Role in Experimental Autoimmune Neuritis by Controlling Peripheral Nervous System Inflammation of Rats.The pathogenic relevance of αM-integrin in Guillain-Barré syndrome.Lesional accumulation of CD8(+) cells in sciatic nerves of experimental autoimmune neuritis rats.Keratan sulfate expression in microglia is diminished in the spinal cord in experimental autoimmune neuritis.Increased circulating Th17 cell populations and elevated CSF osteopontin and IL-17 concentrations in patients with Guillain-Barré syndrome.Endoneurial edema in sural nerve may indicate recent onset inflammatory neuropathy.Curcumin ameliorates rat experimental autoimmune neuritis.Beneficial or Harmful Role of Macrophages in Guillain-Barré Syndrome and Experimental Autoimmune Neuritis.
P2860
Q21296685-93D57691-3454-4FC4-A1BE-2931D2EFC695Q27303465-0A1C286D-4405-4E2B-B69A-6AEA6E12100DQ27322544-04475761-BAB9-405E-A749-0CC58D0F5B0EQ28551190-910D4871-D318-4036-8AE5-B66AC47412DDQ30362413-7D88511C-F632-4818-BF4C-EDBC1E4A1242Q30415924-F069801C-7821-49AD-BFB7-89862F0D3E5CQ30524065-6CDE8086-D572-49FD-980A-F6E2CA5109C9Q33624382-27EF084A-A41C-451C-846C-67F6F4684B7CQ33958127-C13A6538-8CC1-4BE0-858A-11B743D64F31Q34130447-72BC64F7-DF3C-4D13-B4D7-00CC7BD95EABQ34409385-8C360E76-5202-4A58-9EF8-0EA3903BF89AQ35113272-80D4E109-60CE-4B40-B771-EB473B933EE3Q35121614-20889987-ADB6-413D-8A89-0BA0675B471DQ36019417-8428D548-ED98-4049-A0B5-A2777091EE01Q36164126-430A8AB8-F5E0-4FA7-861D-F7A6B681A300Q36189269-ECAEC00E-B118-49C4-B812-2147FF88BE9AQ36345917-5298D053-AEF7-406F-A0A3-9446F8A8A07AQ36414912-F6D327FE-1857-471D-B40A-271F8450D30CQ36455004-DCD1994F-3EE4-4308-A35B-22ACB1903483Q36802945-4AB1D4B3-0AAA-49D1-B00E-4159BB050F7CQ37234270-FECD1979-AE03-4CB2-814B-9F74500B219AQ37425196-465562C5-111A-4CD6-99B0-75308AAB794EQ37550515-AFF6A54D-4B6B-4876-8C90-FB4C81A2C6DEQ37859643-50E06119-E77A-4968-A3DA-08B415DE4961Q39231546-1BA44156-0941-4C3F-AD60-40027B64555FQ39558493-FC09ACA5-F5C3-4537-ABAC-499F348D3328Q40496877-9F859CBF-DF19-4AB6-9D6E-6B5F389D04D9Q41774229-85F8537A-52A4-4D62-AF33-924C6717AD3FQ42241131-26A0702C-505A-4C28-81A7-6D7F7BC93BABQ48583094-7C9B13C9-ED65-459C-84DF-DD0BD3256C9FQ54225096-4A5A6F3E-CC72-4A88-B907-A424490E02D2Q55278773-4E022A4F-C150-4724-8E63-FDF7ED99486D
P2860
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Advances in understanding and ...... the peripheral nervous system.
@ast
Advances in understanding and ...... the peripheral nervous system.
@en
type
label
Advances in understanding and ...... the peripheral nervous system.
@ast
Advances in understanding and ...... the peripheral nervous system.
@en
prefLabel
Advances in understanding and ...... the peripheral nervous system.
@ast
Advances in understanding and ...... the peripheral nervous system.
@en
P2093
P2860
P356
P1433
P1476
Advances in understanding and ...... the peripheral nervous system.
@en
P2093
Bernhard Hemmer
Hugh J Willison
Reinhard Kiefer
P2860
P304
P356
10.1002/MUS.20076
P577
2004-08-01T00:00:00Z